Key Highlights

  • Q3 2026 net revenues of $193.4 million increased 16% year-over-year, driven by 19% global active patient growth
  • Gross Margin improved to 77% from 73% in the prior year, reflecting Manufacturing efficiencies and higher patient volumes
  • Full-year 2026 Revenue guidance raised to $736–$743 million; adjusted EBITDA guidance increased to $24–$34 million
  • Optune Pax received approval from Japan's Ministry of Health for treatment of locally advanced pancreatic cancer

Revenue Growth Driven by Patient Expansion

Novocure (NASDAQ:NVCR), a global oncology company working to extend survival in some of the most aggressive cancers through its Tumor Treating Fields (TTFields) therapy, reported net revenues of $193.4 million for the third quarter ended September 30, 2026. This represents a 16% increase from the same period of 2025, driven by 19% growth in active patients globally.

The United States, Germany, France, and Japan contributed $111.9 million, $24.9 million, $18.7 million, and $14.5 million, respectively, with other active markets contributing $18.8 million. Net revenue also included $4.4 million in one-time benefits in the U.S. and Germany related to higher claims approval rates. As of September 30, 2026, total active patients on TTFields therapy worldwide reached 5,260.

Net revenue from Optune Lua and Optune Pax, newer indications in the company's TTFields portfolio, was $11.9 million. Optune Lua revenue was $8.2 million, while Optune Pax contributed $3.7 million, with substantially all of that from U.S. sales. Revenue from Novocure's Partnership with Zai Lab in Greater China was $4.5 million.

Margins Expand as Profitability Path Advances

Gross margin for Q3 2026 improved to 77% from 73% in the same period of 2025, reflecting the Operating Leverage of higher patient volumes, lower cost of revenues per active patient, improved array utilization, and manufacturing efficiencies. These gains highlight Novocure's ability to scale its TTFields platform cost-effectively as the patient base expands.

Research, development, and clinical study expenses were $58.1 million, an 8% increase, driven primarily by clinical trial expenses for the KEYNOTE D58 study. Sales and Marketing expenses decreased 9% to $53.3 million, and general and administrative expenses declined 5% to $43.6 million, both primarily due to lower share-based compensation. Net loss for the quarter was $10.4 million, with a loss per share of $0.09. Adjusted EBITDA for Q3 2026 was $15.7 million.

Active Patient Growth Across Indications

Optune Gio, Novocure's flagship product for glioblastoma multiforme, had 4,729 active patients globally as of September 30, 2026, an increase of 11% from the same period in 2025. The U.S., Germany, France, and Japan contributed 2,324, 656, 493, and 592 active patients, respectively.

Optune Lua, approved for malignant pleural mesothelioma, saw 255 active patients, an 83% year-over-year increase. Optune Pax, for locally advanced pancreatic cancer, had 276 active patients, with 238 prescriptions received in the quarter. Japan and Germany's Optune Lua patient contributions, at 110 and 42, respectively, highlight the continued global expansion of TTFields beyond glioblastoma.

Guidance Raised and Japan Approval Secured

Following the strong quarter, Novocure raised its full-year 2026 financial guidance. Total net revenue guidance increased to a range of $736 million to $743 million, up from the prior range of $710 million to $725 million. Adjusted EBITDA guidance was raised to $24 million to $34 million. Cash, cash equivalents, and short-term investments were $463.5 million as of September 30, 2026.

In a significant regulatory milestone, Optune Pax received approval from Japan's Ministry of Health, Labour and Welfare for the treatment of adult patients with unresectable locally advanced pancreatic cancer, in combination with chemotherapy. Novocure also entered into a clinical trial collaboration with Verastem Oncology to evaluate TTFields with chemotherapy and VS-7375, an investigational KRAS G12D inhibitor, for locally advanced pancreatic cancer.

Novocure's Q3 2026 results demonstrate that its TTFields platform is gaining traction across multiple cancer indications and geographies. With the Japan approval of Optune Pax, expanding active patient counts, and raised guidance, the company appears to be building momentum toward its long-stated profitability objectives. The clinical pipeline, including KEYNOTE D58, adds potential future growth optionality.

What drove Novocure's 16% revenue growth in Q3 2026?

Revenue growth was primarily driven by a 19% increase in global active patients on TTFields therapy, contributing to higher net revenues across all major markets including the U.S., Germany, France, and Japan.

What is Novocure's updated full-year 2026 guidance?

Novocure raised its full-year 2026 net revenue guidance to $736–$743 million and its adjusted EBITDA guidance to $24–$34 million, both improved from the prior ranges.

What regulatory milestone did Novocure achieve in Q4 2026?

Optune Pax received approval from Japan's Ministry of Health, Labour and Welfare for treating adults with unresectable locally advanced pancreatic cancer, in combination with gemcitabine and nab-paclitaxel.

How many patients are on Novocure's TTFields therapy globally?

As of September 30, 2026, there were 5,260 total active patients on TTFields therapy globally, including 4,729 on Optune Gio, 255 on Optune Lua, and 276 on Optune Pax.